CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer
Status:
Withdrawn
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of 6,8-bis(benzylthio)octanoic
acid (CPI-613) when given together with docetaxel and to see how well they work in treating
patients with stage IIIB or IV non-small cell lung cancer. Drugs used in chemotherapy, such
as CPI-613 and docetaxel, work in different ways to stop the growth of tumor cells, either by
killing the cells, by stopping them from dividing, or by stopping them from spreading.